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Abstract
Gastroenteropancreatic neuroendocrine neoplasms grade 3 (GEP-NENs G3) are rare
tumors. These highly aggressive neoplasms are traditionally treated with platinum-based
chemotherapy in combination with etoposide. Immune checkpoint proteins such as pro-
grammed cell death ligand (PD-L1) may have a role in different cancers allowing them
escape the immune system and hence, progress. We aimed to investigate the immunohisto-
chemical expression of PD-L1 in GEP-NEN G3 and evaluate its correlation to clinical param-
eters. In a cohort of 136 patients, 14 (10%) expressed PD-L1 immunoreactivity; four (3%)
patients in the tumor cells and 10 (7%) had immunoreactive immune cells. PD-L1 expres-
sion did not correlate to clinical parameters, progression-free survival or overall survival. We
conclude that PD-L1 expression is present only in a subset of GEP-NEN G3 patients. Fur-
ther studies are needed to fully understand the role of PD-L1 in patients with GEP-NEN G3,
including the future possibility for treatment with immune checkpoint inhibitors.
Introduction
Neuroendocrine neoplasms (NENs) are rare solid epithelial tumors with neuroendocrine dif-
ferentiation. Histopathologically the tumors show immunoreactivity (IR) for either one or
both of the neuroendocrine biomarkers chromogranin A (CgA) and synaptophysin (Syn) [1,
2]. The subset of tumors originating in the gastrointestinal tract, esophagus and pancreas is
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referred to as gastroenteropancreatic NENs (GEP-NENs) [3]. One third of GEP-NENs present
as cancer of unknown primary location (CUP) [4, 5] but with the major metastatic bulk in the
abdomen. Tumor grade is based on proliferation index and the term GEP-NEN G3 covers
poorly differentiated neuroendocrine carcinoma (NEC) and (the relatively rare) well differen-
tiated G3 neuroendocrine tumor (NET) with Ki-67 index>20% [6].
The majority of patients with G3 tumors are poorly differentiated (NEC) and presents with
advanced, non-resectable disease. These patients receive standard treatment with platinum-
based chemotherapy, i.e. cisplatin/carboplatin combined with etoposide (or irinotecan) [7–9].
However, despite initial response to treatment, the progression-free survival (PFS) and overall
survival (OS) is short in the majority of patients. Surgical intervention is generally only recom-
mended for patients with limited disease [10–13]. In the smaller group of GEP-NET G3
patients most authors favor temozolomide-based chemotherapy, and for these patients surgery
is recommended for similar indications as for GEP-NET G2 tumors [14, 15]. The incidence of
GEP-NEN G3 has gradually increased during the last decade, but treatment efficacy has not
advanced at the same rate [16, 17].
The introduction of immune checkpoint inhibitors represents a paradigm shift in the treat-
ment of various types of cancers, including malignant melanoma, non-small cell lung cancer,
cancer of the urinary tract and some hematological malignancies [18]. Immune check proteins
are regulatory elements on T-cells that modulate T-cell reactivity. Programmed cell death
ligand 1 (PD-L1) and programmed cell death protein 1 (PD-1) are two immune check proteins
that play a major role in cancer immunity [19].
PD-L1 is suggested to halt the immune system by inhibiting the proliferation of T-cells
when binding to its antigen PD1 [20]. PD-L1 binds to PD1 expressed on activated T-cells and
exerts an inhibitory reaction that is mediated through the T-cell receptor (TCR), which in turn
inhibits interleukin 2 production and T-cell proliferation. This interaction also leads to TCR
downregulation during antigen presentation to immature T-cells [21]. This mechanism has
grown to become one of the leading points of investigation in many cancers. Various types of
cancers have evolved into adopting the PD-L1/PD-1 pathways as an escape mechanism that
allows them to proliferate and survive in a host organ [22, 23].
The aim of this study was to evaluate the expression of PD-L1 in GEP-NENs and describe
its relation to other histopathological and clinical parameters including treatment outcome.
Materials and methods
Patient and tumor characteristics
We enrolled 136 patients diagnosed from 1995–2011 from the Nordic NEC study [5], in which
305 patients, diagnosed with GEP-NEN G3 were collected. NEN G3 patients with CUP with
predominant abdominal metastases were also included. Inclusion of patients was based on
availability of tumor tissue resulting in 136 patients included.
Formalin-fixed, paraffin-embedded (FFPE) tissues were immunohistochemically analyzed
and further cross-linked with data from the Nordic NEC registry. Tumor specimens within
this study were obtained at time of diagnosis and before treatment. Due of the retrospective
nature of this study the information about if samples were from the primary tumor or from
metastases is unfortunately not available.
All tumor specimens included were immunoreactive for CgA and/or Syn and Ki-67 was
>20%. All 136 patients were treated with chemotherapy, 130 with platinum-based chemotherapy
and six patients with an alternative chemotherapy that included irinotecan, vincristine or temozo-
lomide. The liver (64%) and lymph nodes (59%) were the most common sites for metastases.
Additional patient characteristics are presented in Table 1.
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Table 1. Clinicopathological characteristics of patients included.
Characteristic n
Sex
Male/Female (%) 79/57 (58/42)
Median age (range) 62 years (25–90)
Ki-67
�55% / >55% (range) 50/86 (20–100)
Chromogranin A
Positive 108
Negative 28
Synaptophysin
Positive 129
Negative 7
Primary Tumor
Oesophageal 5
Gastric 11
Pancreatic 23
Colonic 35
Rectal 10
CUP 41
Other GI 11
Type of sample specimen
Surgical 83
Surgical biopsy 16
Biopsy 37
Histological differentiation
Well differentiated 10
Poorly differentiated 73
Data not available 53
Response according to RECIST criteria
Complete response 5
Partial response 37
Stable disease 36
Progressive disease 38
Missing data 20
Metastases at diagnosis
Liver 87
Lymph node 29
Lung 11
Bone 3
Brain 6
Pathology
Small cell 44
Large cell 92
PD-L1 Immunoreactivity
Positive 14
Negative 122
https://doi.org/10.1371/journal.pone.0243900.t001
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Immunohistochemistry
New 4 μm sections from the FFPE tissue specimens were cut, placed on glass slides (Superfrost
Plus, Menzel Gläser, Braunschweig, Germany) and baked overnight. Tumor specimens were
stained with a primary monoclonal mouse anti-PD-L1 antibody (PD-L1 IHC clone 22C3
pharm Dx, Agilent, USA) and a CD3 antibody (IR50361-2, FLEX Polyclonal Rabbit Anti-
Human CD3, Ready-to-Use (Link), Agilent, USA). All stainings were performed in an auto-
stainer (Link 48, Agilent Dako, Thermo Shanon LTD, United Kingdom) according to manu-
facturer instructions. Controls in the form of one negative cell line (MCF-7) and one positive
(NCI-H226) are incorporated in the commercial kit for the PD-L1 antibody.
The proportions of immunoreactive tumor cells (TCs) and immunoreactive tumor-infil-
trating immune cells (ICs) were annotated separately. TC IR was defined as partial membrane
staining of any intensity as proportion of TCs with the following increments: 1%, 2%, 3%, 4%,
5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, and 100%. IC positivity was seen as both
cytoplasmic and membranous and hence defined as any positivity (membrane and cyto-
plasmic) as proportion of ICs, which were evaluated independently. The annotation was per-
formed under the supervision of an experienced pathologist.
Photographs were taken using a Zeiss Observer Z1 microscope connected with an AxioCam
MRc5 and the Zeiss Zen software (Carl Zeiss, Gottingen, Germany).
Statistical analysis
The clinical variables chosen to be investigated in the statistical analyses included gender, age, Ki-
67 index, C-reactive protein (CRP), CgA, Syn, therapeutic response (evaluated according to the
RECIST 1.0 criteria), survival and small cell/large cell morphology. The Chi-2 test was used for
calculating correlations of categorical variables e.g. Ki-67 (<55% and>55%), CgA (positive and
negative), Syn (positive and negative), sex (female and male), and morphology (small cell and
large cell). Spearman’s correlation test was used for correlations between continuous variables.
Survival was evaluated through the Kaplan-Meier analysis. Mann-Whitney test was used to
compare PFS and OS between PD-L1-non-immunoreactive patients and PD-L1- immunoreactive
patients. PFS was defined as the time from first treatment to progression or death of any cause. OS
was defined as survival time calculated from the date of diagnosis to date of death of any cause.
All statistical analyses were performed using IBM SPSS statistics software (v25, USA).
Ethics
Local ethics committees in the Nordic countries from which tissue samples were collected
approved the research protocol. The study was approved and the need for new consent was
waived by the local ethics committee, Regionala etikprövningsnämnden (EPN, Dnr 2008/397),
in Uppsala, Sweden.
Results
PD-L1 immunoreactivity in tumor samples
PD-L1 IR was defined as TCs and/or ICs with positive staining. A total of 14 of the 136 (10%)
G3 GEP-NEN tumor specimens studied showed IR.
Four (3%) samples were PD-L1- immunoreactive (>1%) in TCs and 10 (7%) in ICs. A high
frequency of IR (>50% immunoreactive cells) was only seen in one case (0.7%). Among the
four patients with PD-L1 immunoreactive tumors, three had the primary tumor located in the
colon and one had a CUP. Representative photos of immunoreactive and non-immunoreac-
tive stainings are shown in Fig 1.
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In the 10 specimens with PD-L1 expression in ICs, immunoreactive ICs were predomi-
nantly seen in lymphocytes in the periphery of the tumor, giving a capsule-like pattern.
Patients with immunoreactive ICs had primary tumors in the stomach (n = 2), pancreas
(n = 2), colon (n = 2) and CUP (n = 4), Table 2. Representative photos of immunoreactive
stainings are shown in Fig 2.
CD3 and PD-L1 stainings of consecutive sections showed that some ICs also were PD-L1
immunoreactive, Fig 3.
PD-L1 expression in TCs and ICs did not correlate to each other. In contrast, positivity was
exclusive to either TCs or ICs within one tumor specimen.
PD-L1 expression and clinical parameters
Most GEP-NEC G3 tumor specimens with TC PD-L1 IR were located in the colon (n = 3)
which represents 6% of all included colonic NEC. The positivity for ICs was not associated to
any specific tumor site. None of the clinical parameters (age, sex, performance status, Ki-67,
morphology) correlated to PD-L1 expression (S1 Table).
The median PFS was 5.1 months in PD-L1 immunoreactive patients compared to 4.5
months in PD-L1 non-immunoreactive. The median OS was 13.6 months in patients with
PD-L1 immunoreactive tumors compared to 15.1 months in PD-L1 non-immunoreactive.
These differences were not statistically significant.
Survival analysis revealed no statistically significant difference in PFS or OS between
patients with IR in TCs only compared with patients with IR in ICs only. Data is presented in
Fig 4.
Discussion
In this study, we aimed to examine the protein expression of PD-L1 in tumor specimens
derived from 136 patients with GEP-NEN G3 and compare the expression with clinical param-
eters and outcome. To our knowledge, this is the first study of PD-L1 expression in a large
cohort of patients with GEP-NEN G3. Ten percent of the included patients had tumors that
were immunoreactive either in TCs or in ICs, with expression in ICs being more frequent.
This is in concordance with previously reported results [24].
Fig 1. Representative pictures of PD-L1 immunohistochemical staining on tumors. (a) Colon primary tumor with
approximately 4% of all tumor cells immunoreactive. Insert, magnification. (b) Colon primary with 80%
immunoreactive tumor cells. (c) Non-immunoreactive colon primary tumor. Scale bars 50 μm.
https://doi.org/10.1371/journal.pone.0243900.g001
Table 2. Results from immunohistochemical evaluation.
Primary tumor site PD-L1 Immunoreactivity TCs1 (n) PD-L1 Immunoreactivity ICs2 (n)
Esophagus 0 0
Stomach 0 2
Pancreas 0 2
Colon 3 2
Rectum 0 0
CUP 1 4
Total 4 10
1TC, Tumor Cell
2IC, Immune cell.
https://doi.org/10.1371/journal.pone.0243900.t002
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Expression of PD-L1 has been studied in many cancers including GEP-NENs. A limitation
with studies on GEP-NENs is usually that NENs belonging to the three different grades (G1,
G2 and G3) are included in the same study. One study showed that PD-L1 was not correlated
to metastatic disease but was seen in patients with high WHO grade [25]. In a study by Bösch
et al., PD-L1 could not be associated to tumor grade [26]. Another study demonstrated that
21.9% patients were PD-L1 immunoreactive and that PD-L1 expression was significantly cor-
related to a higher WHO grade [27]. PFS and OS were also significantly poorer for patients
with PD-L1 IR than those that were non-immunoreactive. Similar results were reported in
another study of 57 patients of G1, G2 and G3 tumors where all the G3 tumors (n = 9) were
PD-L1 immunoreactive, and expression correlated to poorer outcome [28]. However, we
could not confirm that PD-L1 expression correlates to PFS or OS in this cohort which solely
includes G3 patients.
In this study, the four tumors that were PD-L1 immunoreactive in TCs were poorly-differ-
entiated. Three out of the four patients had primaries located in the colon, which in general is
considered to be the most aggressive sub-group of GEP-NEN G3. In contrast, the 10 patients
who showed PD-L1 IR in ICs had primaries in the stomach, pancreas, colon and CUP. This
might imply that PD-L1 could be more frequently expressed in TCs in the more aggressive
tumors, but our data cannot confirm this.
There was no statistical correlation between PD-L1 expressing tumors and clinical variables
in our study. The lack of correlation to outcome compared to that which has been found in
other studies [27, 28], could be due to the low frequency of immunoreactive tumors and also
that all patients in this study belonged to the G3 group. It is uncertain how the presence of
immunoreactive ICs should be evaluated and what their clinical relevance is. Furthermore,
this study is based on data collected retrospectively. There was no treatment intervention with
immune-check inhibitors in these patients to evaluate whether the expression in samples in
this study could be correlated to the clinical outcome in treatment with immune-check
Fig 2. Representative pictures of PD-L1 immunohistochemical staining on immune cells. (a) Gastric primary
tumor without IR for PD-L1 in tumor cells but with PD-L1 immunoreactive immune cells in stroma. Insert,
magnification. (b) Cancer of unknown primary with PD-L1 immunoreactive immune cells infiltrating tumor
environment. (c) Cancer of unknown primary with PD-L1 immunoreactive immune cells in a capsule-like pattern.
Scale bars 50 μm.
https://doi.org/10.1371/journal.pone.0243900.g002
Fig 3. Representative pictures of immune cells immunoreactive for PD-L1 and CD3. (a) Red arrow marked immune cell
immunoreactive for PD-L1. (b) Red arrow showing same cells immunoreactive for CD3. Scale bar 100 μm. Inserts, magnification.
Scale bars 50 μm.
https://doi.org/10.1371/journal.pone.0243900.g003
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inhibitors as seen in other studies [29, 30]. Adding complexity to this is the fact that there are
different assays and antibodies that have different cut-offs and different guidelines for evalua-
tions [31]. One study suggests a new method of evaluating PD-L1 IR which seems to pave way
for simpler evaluations. This study proposes a combined positive score (CPS), by combining
the score of immunoreactive TCs and ICs in a fraction, compared to all available tumor cells.
This offers a more reproducible evaluation technique which significantly correlates to the
objective response to pembrolizumab in the KEYNOTE-059 study, while PD-L1 expression on
only TCs did not [32].
Another factor of importance is that chemotherapy and genetic alterations might have an
impact on the expression of PD-L1. Oxaliplatin may reduce the expression of PD-L2 [33] and
thereby limit the immuno-suppression by dendritic cells [34]. On the other hand, cisplatin has
been shown to result in an overexpression of PD-L1 [35]. One study has shown that when cis-
platin was below IC50, it induced the expression of PD-L1 and PD-1 in hepatoma H22 cells
[35]. Mutations in p53 have also been linked to PD-L1 expression and clinical relevance [36].
Tumor specimens within this study were obtained before any treatment. However, these are
Fig 4. Kaplan-Meier curves for progression-free survival and overall survival. (a) and (b); specimens with PD-L1 IR in
tumor cells and specimens with PD-L1 IR in immune cells, compared to PD-L1 non-immunoreactive specimens. (c) and (d);
comparison between patients with only tumor cells immunoreactive for PD-L1 versus patients with only immune cells
immunoreactive for PD-L1. (e) and (f); comparison between patients with tumor cells and/or immune cells immunorective
for PD-L1 versus PD-L1 non-immunoreactive patients.
https://doi.org/10.1371/journal.pone.0243900.g004
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very important factors in trying to understand the clinical value and mechanisms of PD-L1
expression on TCs.
In conclusion, expression of PD-L1 in GEP-NENs G3 may be detected in a subgroup of
patients but the clinical relevance of this expression is debated. Further studies are needed,
preferably with larger cohorts, and a consensus on pathological evaluation, which may provide
more evidence for the relevance of PD-L1 expression in GEP-NENs G3. The importance of
tumor mutational burden as well as treatment are essential parameters which should be con-
sidered in the future evaluation of PD-L1.
Supporting information
S1 Table. PD-L1 expression in relation to clinicopathological variables. aChi-square test for
independence. bSpearman’s correlation test coefficient.
(DOCX)
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